The minimum inhibitory concentrations (MICs) of common antibiotics (National Institutes for Food and Drug Control, Beijing, China) against ESBL-producing E. coli were determined using the broth microdilution method with E. coli ATCC 25922 as the control strain. Interpretation of results followed the criteria of CLSI 201328 . The interpretation breakpoint of cefoperazone/Sulbactam (Pfizer Inc., USA) was extrapolated from that of cefoperazone, and those of tigecycline and colistin (Pfizer Inc.) were based on the criteria of the European Committee on Antimicrobial Susceptibility Testing (EUCAST-2012).
Cefoperazone
Manufactured by Pfizer
Sourced in United States
Cefoperazone is a semisynthetic cephalosporin antibiotic used in the treatment of various bacterial infections. It functions as an inhibitor of bacterial cell wall synthesis, thereby disrupting the structural integrity of the bacterial cell.
Automatically generated - may contain errors
4 protocols using cefoperazone
1
Antibiotic Susceptibility of ESBL-Producing E. coli
2
Non-lethal Mouse Model of C. difficile
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Intestinal colonization of select C. difficile strains was assessed using a non-lethal mouse model of infection [30 (link)]. 10-week-old male C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME, USA) were pre-treated with cefoperazone (0.5 mg/mL) in the drinking water for 10 days, followed by intraperitoneal clindamycin (10 mg/kg) (Pfizer, New York, NY, USA) on day −1. The animals were administered 106 spores of BI-1, GV106, GV135, or GV148, via oral gavage on day 0 (N = 5/group). Animals were weighed once daily and monitored twice daily for signs of stress. Surviving animals were humanely euthanized at the end of the study using a commercial euthanasia solution described above. Stool pellets or cecal content were collected daily, resuspended, homogenized in PBS, serially diluted, and plated onto TCCFA for isolation and bacterial burden (CFU/g of stool or cecal tissue).
3
Pharmacokinetics of Cefoperazone/Sulbactam
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
cefoperazone/sulbactam (Sulperazon, Pfizer, New York, USA) in 1.5-g ampoules with cefoperazone 1.0 g/sulbactam 0.5g was given to all included patients. All the patients were given cefoperazone/sulbactam 3.0 g in 50-mL saline by intravenous injection for 3 hours every 6 hours after craniotomy. 1.5mL of venous blood and 1.5 mL of CSF were collected before the start of drug administration and at Hour 1, 2, 3, 4, 6, 12, 15, 16, 18 h after administration. The specimens were centrifuged at a speed of 3500 r/min for 5 min. Then, the supernatant was collected and stored at −70°C for uniform testing.
4
Combination Therapy for Pan-resistant Acinetobacter baumannii
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The extracted pan-resistant Acinetobacter baumannii was observed immediately and was divided into colonized bacteria and infectious bacteria according to the hospital infection diagnostic criteria established by the Ministry of Health. The extracted bacterium was defined as colonized bacteria if it did not qualify for the diagnostic criteria (6 (link)).
The treatment effects of groups A and B were retrospectively analyzed. The antibacterial drugs employed in group A were a combination of cefoperazone, sulbactam (Pfizer, NY, USA) and tanreqing (Kangbao, Shanxi, China). cefoperazone (2 g) and sulbactam (3 g) were administered by intravenous drip every 8 h. Tanreqing (20 ml) was then added into the intravenous drip once a day. For group B, the cases were treated with only cefoperazone and sulbactam. The curative effect and prognosis of the two groups were recorded and the remaining treatments were administered as per clinical routine. The effects were evaluated based on the guiding principles of clinical research on antibacterial agents, as established released by the Ministry of Health (7 (link)). The main criteria for the clinical effects were symptom, sign and laboratory inspection. The 4 grades for assessment were: recovery, significantly improved, improved and no response. In addition, mortality within 28 days after infection was observed.
The treatment effects of groups A and B were retrospectively analyzed. The antibacterial drugs employed in group A were a combination of cefoperazone, sulbactam (Pfizer, NY, USA) and tanreqing (Kangbao, Shanxi, China). cefoperazone (2 g) and sulbactam (3 g) were administered by intravenous drip every 8 h. Tanreqing (20 ml) was then added into the intravenous drip once a day. For group B, the cases were treated with only cefoperazone and sulbactam. The curative effect and prognosis of the two groups were recorded and the remaining treatments were administered as per clinical routine. The effects were evaluated based on the guiding principles of clinical research on antibacterial agents, as established released by the Ministry of Health (7 (link)). The main criteria for the clinical effects were symptom, sign and laboratory inspection. The 4 grades for assessment were: recovery, significantly improved, improved and no response. In addition, mortality within 28 days after infection was observed.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!